Topical ingenol mebutate treatment is known to cause a pronounced recruitment of neutrophils to the treatment site [9,17,20,21], with IL-1 previously shown to promote the anti-cancer activities of neutrophils in the B16 model [35,48]. Here, IL1A is linked to cancer.